1. Home
  2. EGG vs IPHA Comparison

EGG vs IPHA Comparison

Compare EGG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EGG
  • IPHA
  • Stock Information
  • Founded
  • EGG 2010
  • IPHA 1999
  • Country
  • EGG Singapore
  • IPHA France
  • Employees
  • EGG N/A
  • IPHA N/A
  • Industry
  • EGG Professional Services
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EGG Consumer Discretionary
  • IPHA Health Care
  • Exchange
  • EGG Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • EGG 176.4M
  • IPHA 160.1M
  • IPO Year
  • EGG 2025
  • IPHA 2019
  • Fundamental
  • Price
  • EGG $5.79
  • IPHA $2.03
  • Analyst Decision
  • EGG
  • IPHA Strong Buy
  • Analyst Count
  • EGG 0
  • IPHA 1
  • Target Price
  • EGG N/A
  • IPHA $11.00
  • AVG Volume (30 Days)
  • EGG 764.0K
  • IPHA 6.5K
  • Earning Date
  • EGG 01-01-0001
  • IPHA 09-11-2025
  • Dividend Yield
  • EGG N/A
  • IPHA N/A
  • EPS Growth
  • EGG N/A
  • IPHA N/A
  • EPS
  • EGG 0.09
  • IPHA N/A
  • Revenue
  • EGG $5,500,473.00
  • IPHA $20,831,349.00
  • Revenue This Year
  • EGG N/A
  • IPHA $209.83
  • Revenue Next Year
  • EGG N/A
  • IPHA $83.15
  • P/E Ratio
  • EGG $66.66
  • IPHA N/A
  • Revenue Growth
  • EGG N/A
  • IPHA N/A
  • 52 Week Low
  • EGG $2.53
  • IPHA $1.29
  • 52 Week High
  • EGG $13.88
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • EGG N/A
  • IPHA 61.46
  • Support Level
  • EGG N/A
  • IPHA $1.71
  • Resistance Level
  • EGG N/A
  • IPHA $1.98
  • Average True Range (ATR)
  • EGG 0.00
  • IPHA 0.07
  • MACD
  • EGG 0.00
  • IPHA 0.04
  • Stochastic Oscillator
  • EGG 0.00
  • IPHA 83.65

About EGG Enigmatig Limited Class A Ordinary Shares

Enigmatig Ltd is an international consultancy firm providing one-stop cross-border licensing solutions and related services. Its services range from assisting clients in incorporating companies in overseas jurisdictions and related corporate secretarial services to a wide range of licensing and regulatory maintenance services. Its clients consist of small and medium-sized corporations setting up contracts for different brokerage businesses, in particular foreign exchange brokerage businesses in overseas jurisdictions. Its corporate services income is mainly generated from fees received assisting its clients to obtain, renew and comply with a range of business licenses (including brokerage licenses and other financial licenses) in a variety of jurisdictions (in London, Cyprus and Belize).

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: